VAXX - Vaxxinity to Present at Upcoming November Medical and Investor Conferences | Benzinga
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November.
Vaccines Summit – 2023
Date: Tuesday, November 14, 2023
Time: 12:20 – 12:40 p.m. (ET)
Title: UB-612: A novel peptide/protein subunit COVID-19 vaccine booster stimulated broadly neutralizing and Fc-mediated effector antibodies in a head-to-head Phase 3 randomized clinical trial
Jefferies London Healthcare Conference
Date: Wednesday, November 15, 2023
Time: 4:30 – 4:55 p.m. (GMT)
Format: Fireside chat
Evercore ISI 6th Annual HealthCONx Conference
Date: Wednesday, November 29, 2023
Time: 10:25 – 10:45 a.m. (ET)
Format: Fireside chat
Presentation times are subject to change.
About Vaxxinity
Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel synthetic peptide immunotherapy candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's disease, Parkinson's disease, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially ...